The Association of Hemoglobin A1c With Incident Heart Failure Among People Without Diabetes: The Atherosclerosis Risk in Communities Study
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
19/10/2012
19/10/2012
2010
|
Resumo |
OBJECTIVE-This study sought to investigate an association of HbA1c (A1C) with incident heart failure among individuals without diabetes and compare it to fasting glucose. RESEARCH DESIGN AND METHODS-We studied 11,057 participants of the Atherosclerosis Risk in Communities (ARIC) Study without heart failure or diabetes at baseline and estimated hazard ratios of incident heart failure by categories of A1C (<5.0, 5.0-5.4 [reference], 5 5-59, and 6.0-6.4%) and fasting glucose (<90, 90-99 [reference], 100-109, and 110-125 mg/dl) using Cox proportional hazards models. RESULTS-A total of 841 cases of incident heart failure hospitalization or deaths (International Classification of Disease, 9th/10th Revision, 428/150) occurred during a median follow-up of 14.1 years (incidence rate 5.7 per 1,000 person-years). After the adjustment for covariates including fasting glucose, the hazard ratio of incident heart failure was higher in individuals with A1C 6.0-6.4% (1.40 [95% CI, 1 09-1.79]) and 5.5-6.0% (1.16 [0.98-1 37]) as compared with the reference group. Similar results were observed when adjusting for insulin level or limiting to heart failure cases without preceding coronary events or developed diabetes during follow-up. In contrast, elevated fasting glucose was not associated with heart failure after adjustment for covariates and A1C. Similar findings were observed when the top quartile (A1C, 5.7-6.4%, and fasting glucose, 108-125 mg/dl) was compared with the lowest quartile (<5 2% and <95 mg/dl, respectively). CONCLUSIONS-Elevated A1C (>= 5.5-6 0%) was associated with incident heart failure in a middle-aged population without diabetes, suggesting that chronic hyperglycemia prior to the development of diabetes contributes to development of heart failure. Diabetes 59:2020-2026, 2010 National Heart, Lung, and Blood Institute (NHLBI/NIH)[N01-HC-55015] National Heart, Lung, and Blood Institute (NHLBI/NIH)[N01-HC-55016] National Heart, Lung, and Blood Institute (NHLBI/NIH)[N01-HC-55018] National Heart, Lung, and Blood Institute (NHLBI/NIH)[N01-HC-55019] National Heart, Lung, and Blood Institute (NHLBI/NIH)[N01-HC-55020] National Heart, Lung, and Blood Institute (NHLBI/NIH)[N01-HC-55021] National Heart, Lung, and Blood Institute (NHLBI/NIH)[N01-HC-55022] NIH/NIDDK[R21-DK-080294] NIH/NIDDK[K01-DK-076595] NIH/NIDDK[R01-DK-076770] NIH/NHLBI[5T32-HL-007024] |
Identificador |
DIABETES, v.59, n.8, p.2020-2026, 2010 0012-1797 http://producao.usp.br/handle/BDPI/24133 10.2337/db10-0165 |
Idioma(s) |
eng |
Publicador |
AMER DIABETES ASSOC |
Relação |
Diabetes |
Direitos |
restrictedAccess Copyright AMER DIABETES ASSOC |
Palavras-Chave | #IMPAIRED GLUCOSE-TOLERANCE #CARDIOVASCULAR RISK #GLYCATED HEMOGLOBIN #GLYCEMIC CONTROL #FASTING GLUCOSE #PLASMA-GLUCOSE #MORTALITY #OUTCOMES #DISEASE #HOSPITALIZATION #Endocrinology & Metabolism |
Tipo |
article original article publishedVersion |